Accueil   Diary - News   All news iDD biotech is granted new Patents in the USA and in China about its Fc optimized MAbs anti-CD19

iDD biotech is granted new Patents in the USA and in China about its Fc optimized MAbs anti-CD19

iDD biotechTwo  important  MAbs  of  iDD  biotech  have  been  granted  new  Patents abroad: in  the  USA  for  iDD002  (US  Patent  No.  9,120,856)  and in China  for  iDD001 (WO 2012/010562).

 

 

These two new patents will support the development of therapeutic MAb anti-CD19, with high killing activity against many CD19 positive B cell malignancies.

 

From   its   proprietary   MAb   libraryand   by   using   its  MAb   design advanced   platform (WO2012/010602), iDD biotech has generated next generation, pro-apoptotic humanized, Fc optimized  and  afucosylated  MAbs  to  enhance antibody  dependent  cellular  cytotoxicity (ADCC), with  or  without complement  dependent  cytotoxicity  (CDC) activities, respectively IDD001 and  IDD002. Their  potent in  vitro and in  vivo activity  against  B-LAL  have  been demonstrated.

 

Read the  press release

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree